TrialCancer science2019

Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.

Hiroaki Shima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.